{"id":3858,"date":"2018-12-21T14:55:11","date_gmt":"2018-12-21T09:25:11","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3858"},"modified":"2021-07-24T12:57:09","modified_gmt":"2021-07-24T07:27:09","slug":"the-business-cocktail-48","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-48","title":{"rendered":"Tetra, Shionogi sign deal; Amgen remunerates; Gilead\u2019s fibrotic disease deal"},"content":{"rendered":"\n<p><strong>Tetra,\nShionogi sign USD 40 Million deal for Alzheimer\u2019s disease and fragile X\nsyndrome<\/strong><\/p>\n\n\n\n<p><strong>Tetra Discovery Partners<\/strong> is&nbsp;collaborating&nbsp;with <strong>Shionogi<\/strong> to progress its PDE4-targeting drug in<a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\"> <strong>Alzheimer\u2019s disease<\/strong><\/a> and <strong>fragile X syndrome<\/strong>. Shionogi will give a <strong>USD 5 million<\/strong> upfront payment and USD 35 million in equity. This will let Tetra earn up to USD 120 million in development and commercial milestones.&nbsp;The USD 40 million will let <strong>Michigan-based Tetra<\/strong> to finish an ongoing <strong>phase 2 trial<\/strong> in fragile X and to start another phase 2 trial in early Alzheimer\u2019s disease. <\/p>\n\n\n\n<p><strong>Amgen\nremunerates USD 50 Million for preclinical bispecific of Molecular Partners&nbsp; <\/strong><\/p>\n\n\n\n<p><strong>Amgen <\/strong>is&nbsp;remunerating&nbsp;<strong>Molecular Partners<\/strong> USD 50 million for global rights to preclinical anti-cancer immune cell activator <strong>MP0310<\/strong>. The Molecular partners will examine the 4-1BB-FAP bispecific molecule in combination with Amgen drugs including its bispecific T-cell engagers. Antibodies that target T cell co-stimulatory receptor 4-1BB, also known as CD137, have exacerbated in animal models, but the field has been hindered by hepatotoxicity and struggles to translate the efficacy seen in preclinical into the clinic. Molecular Partners responded to the highs and lows of 4-1BB drug development by developing a drug designed to hit the target and FAP simultaneously.<\/p>\n\n\n\n<p><strong>Gilead\nhands Scholar Rock USD 80 Million in fibrotic disease agreement<\/strong><\/p>\n\n\n\n<p><strong>Gilead and Scholar Rock<\/strong> are&nbsp;collaborating for fibrotic diseases that hinder the activation of <strong>transforming growth factor beta (TGF\u03b2)<\/strong>. Gilead is giving USD 80 million upfront for the exclusive option to permit global rights to three Scholar Rock programs. The companies revealed two of Scholar Rock\u2019s programs- inhibitors targeting the activation of latent TGF\u03b21 with high affinity and specificity and those that target latent TGF\u03b21 in the extracellular matrix.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tetra, Shionogi sign USD 40 Million deal for Alzheimer\u2019s disease and fragile X syndrome Tetra Discovery Partners is&nbsp;collaborating&nbsp;with Shionogi to progress its PDE4-targeting drug in Alzheimer\u2019s disease and fragile X syndrome. Shionogi will give a USD 5 million upfront payment and USD 35 million in equity. This will let Tetra earn up to USD 120 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3483,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[72,831,750,794,2343,2344,2342,2341,2345],"industry":[17225],"therapeutic_areas":[17245,17234],"class_list":["post-3858","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alzheimers-disease","tag-amgen","tag-fragile-x-syndrome","tag-gilead","tag-molecular-partners","tag-scholar-rock","tag-shionogi","tag-tetra-discovery-partners","tag-transforming-growth-factor-beta-tgf","industry-pharmaceutical","therapeutic_areas-neurology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Tetra, Shionogi sign deal; Amgen remunerates; Gilead\u2019s fibrotic disease<\/title>\n<meta name=\"description\" content=\"Tetra Discovery Partners is collaborating with Shionogi to progress its PDE4-targeting drug in Alzheimer&#039;s disease.......\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-48\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tetra, Shionogi sign deal; Amgen remunerates; Gilead\u2019s fibrotic disease\" \/>\n<meta property=\"og:description\" content=\"Tetra Discovery Partners is collaborating with Shionogi to progress its PDE4-targeting drug in Alzheimer&#039;s disease.......\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-48\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-12-21T09:25:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022444\/maxresdefault.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1547\" \/>\n\t<meta property=\"og:image:height\" content=\"943\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tetra, Shionogi sign deal; Amgen remunerates; Gilead\u2019s fibrotic disease","description":"Tetra Discovery Partners is collaborating with Shionogi to progress its PDE4-targeting drug in Alzheimer's disease.......","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-48","og_locale":"en_US","og_type":"article","og_title":"Tetra, Shionogi sign deal; Amgen remunerates; Gilead\u2019s fibrotic disease","og_description":"Tetra Discovery Partners is collaborating with Shionogi to progress its PDE4-targeting drug in Alzheimer's disease.......","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-48","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-12-21T09:25:11+00:00","article_modified_time":"2021-07-24T07:27:09+00:00","og_image":[{"width":1547,"height":943,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022444\/maxresdefault.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-48","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-48","name":"Tetra, Shionogi sign deal; Amgen remunerates; Gilead\u2019s fibrotic disease","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-48#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-48#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022444\/maxresdefault.jpg","datePublished":"2018-12-21T09:25:11+00:00","dateModified":"2021-07-24T07:27:09+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Tetra Discovery Partners is collaborating with Shionogi to progress its PDE4-targeting drug in Alzheimer's disease.......","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-48"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-48#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022444\/maxresdefault.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022444\/maxresdefault.jpg","width":1547,"height":943,"caption":"Gilead"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022444\/maxresdefault-300x183.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Amgen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Fragile X syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gilead<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Molecular Partners<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Scholar Rock<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Shionogi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Tetra Discovery Partners<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">transforming growth factor beta (TGF\u03b2)<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Amgen<\/span>","<span class=\"advgb-post-tax-term\">Fragile X syndrome<\/span>","<span class=\"advgb-post-tax-term\">Gilead<\/span>","<span class=\"advgb-post-tax-term\">Molecular Partners<\/span>","<span class=\"advgb-post-tax-term\">Scholar Rock<\/span>","<span class=\"advgb-post-tax-term\">Shionogi<\/span>","<span class=\"advgb-post-tax-term\">Tetra Discovery Partners<\/span>","<span class=\"advgb-post-tax-term\">transforming growth factor beta (TGF\u03b2)<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Dec 21, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Dec 21, 2018 2:55 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3858","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3858"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3858\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3483"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3858"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3858"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3858"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3858"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3858"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}